Drug-induced extrapyramidal symptoms: their incidence and treatment.
D002746:Chlorpromazine / Q000009:adverse effects; D002749:Chlorprothixene / Q000009:adverse effects; D005116:Extrapyramidal Tracts / Q000187:drug effects*; D005260:Female; D005476:Fluphenazine / Q000009:adverse effects; D006801:Humans; D008297:Male; D010276:Parasympatholytics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy; D010302:Parkinson Disease, Secondary / Q000139:chemically induced*; D010546:Perphenazine / Q000009:adverse effects; D010640:Phenothiazines / Q000009:adverse effects; D011346:Prochlorperazine / Q000009:adverse effects; D013881:Thioridazine / Q000009:adverse effects; D014149:Tranquilizing Agents / Q000009:adverse effects*; D014268:Trifluoperazine / Q000009:adverse effects
D010276:Parasympatholytics; D010640:Phenothiazines; D014149:Tranquilizing Agents; D014268:Trifluoperazine; D002749:Chlorprothixene; D010546:Perphenazine; D013881:Thioridazine; D005476:Fluphenazine; D002746:Chlorpromazine; D011346:Prochlorperazine